Your session is about to expire
← Back to Search
ADI-PEG 20 + Chemotherapy for Leiomyosarcoma
Study Summary
This trial compares the effectiveness and safety of a new treatment for a type of cancer that has already had an existing treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals are currently participating in this research?
"Affirmative. According to the data provided by clinicaltrials.gov, this medical trial is still actively looking for patients and was first posted on November 1st 2023 with its last edit being made on November 27th of that same year. The study requires 300 participants across one location."
Are elderly individuals over 70 years old welcome to participate in this trial?
"According to the study's eligibility parameters, those hoping to be considered must lie between 18 and 99 years of age. There are 150 medical trials limited to younger participants and 386 options for senior citizens in need of treatment."
Are there vacancies still available for participants in this investigation?
"According to clinicaltrials.gov, this investigation is currently recruiting participants; the trial was initially published on November 1st 2023 and most recently modified on November 27th of that year."
Has the FDA authorized ADIGemDoc for use?
"According to our estimation, ADIGemDoc is classified as 'safe' on a scale of 1-3 due to Phase 3 trial results that demonstrate its efficacy and reliability."
Is it feasible for me to join the research endeavor?
"This medical experiment is accepting 300 individuals aged 18 to 99 who have been diagnosed with soft tissue sarcoma. Furthermore, they must meet the criteria outlined in Appendixes A and B of this trial: Histologically or cytologically verified grade 2 or 3 LMS STS, confirmation of subtype (uterine/non-uterine), measurable disease per RECIST 1.1, prior treatment up to two systemic regimens including doxorubicin therapy more than one year ago in adjuvant/neoadjuvant setting; age over 18 years old; ECOG performance status less than 1 at enrollment; leukocytes"
Share this study with friends
Copy Link
Messenger